Gelteq shares rise 50.64% intraday after preclinical results show 22% higher CBD bioavailability via oral gel platform.

Gelteq Ltd (NASDAQ:GELS) surged 50.64% during intraday trading following the release of positive preclinical results demonstrating its proprietary oral gel platform enhances cannabidiol (CBD) bioavailability by over 22% compared to an FDA-approved oil-based product. The findings validate Gelteq’s ability to deliver higher peak exposure and efficient absorption of lipophilic cannabinoids at lower concentrations, positioning the company for potential expedited market entry in Australia via the Special Access Scheme. This breakthrough strengthens its competitive edge in the medicinal cannabis sector and paves the way for global expansion, driving immediate investor optimism. The intraday rally aligns with pre-market momentum reported by Benzinga and TheFly, underscoring strong market confidence in the company’s innovation and commercialization prospects.